65
Views
6
CrossRef citations to date
0
Altmetric
Original Research

Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung

, , , , , , , , , , , & show all
Pages 8565-8573 | Published online: 30 Nov 2018

Reprints and Permissions

Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.

To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.

For more information please visit our Permissions help page.